Zynex Inc. (OTCMKTS:ZYXI) – Investment analysts at Seethru Equity dropped their FY2018 earnings estimates for Zynex in a report released on Tuesday, May 15th. Seethru Equity analyst A. Tandon now forecasts that the company will post earnings of $0.30 per share for the year, down from their prior forecast of $0.31.
Other research analysts have also issued reports about the company. Zacks Investment Research raised Zynex from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a report on Thursday, March 15th. ValuEngine lowered Zynex from a “buy” rating to a “hold” rating in a report on Friday, May 11th.
Shares of OTCMKTS ZYXI opened at $3.20 on Friday. Zynex has a one year low of $0.30 and a one year high of $5.50. The firm has a market capitalization of $101.14 million, a price-to-earnings ratio of 10.91 and a beta of 0.93.
Zynex (OTCMKTS:ZYXI) last posted its earnings results on Tuesday, May 8th. The company reported $0.06 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.06. The business had revenue of $6.88 million for the quarter, compared to analyst estimates of $6.73 million. Zynex had a return on equity of 356.96% and a net margin of 33.24%.
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.